Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a sell rating to a hold rating in a report issued on Saturday.

Several other equities research analysts have also issued reports on ARTV. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $6.74 on Friday. The firm has a market cap of $166.59 million, a PE ratio of -1.97 and a beta of 1.46. The firm’s 50 day moving average price is $5.14 and its 200 day moving average price is $4.28. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $7.75.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.03. On average, sell-side analysts anticipate that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth $79,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $58,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $67,000. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter worth $53,000. Finally, BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the period.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.